Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Behav Brain Res. 2017 Jul 19;334:1–5. doi: 10.1016/j.bbr.2017.07.020

Figure 2.

Figure 2

The AMPAkine CX546 can exert its analgesic effects in the prefrontal cortex (PFC). A. Schematic for the experimental design. CX546 or saline was delivered via intracranial cannulas into the prelimbic region of the PFC. Following intracranial drug delivery, rats underwent Hargreaves’ tests. B. Intra-PFC delivery of CX546 caused an increase in the latency to paw withdrawals. Unpaired Student’s t test. n=8, * p=0.0124. C. Schematic for the experimental design. CX546 (800 μM/μl) or saline was delivered via intracranial cannulas into the PFC; at approximately the same time, morphine (1mg/kg) was administered IP. Following intracranial and systemic drug deliveries, rats underwent Hargreaves’ tests. D. Intra-PFC delivery of CX546, compared with saline, caused an additional increase in the latency to paw withdrawals in rats that received morphine injections. Unpaired Student’s t test. n=8, ** p=0.0099.